

Dead Sea topical effects scientifically approved data: Present status and new directions

Meital Portugal-Cohen

AHAVA Dead Sea laboratories, Israel

Since ancient time, Dead Sea (DS) aroused surprising degree of interest as a result of its exclusive location 427 meter below sea level, chemical composition and atmospheric properties.

The DS area is unique for its natural therapeutic resources including exceptional composition of sun rays due to low altitude as well as unusual blend of minerals in DS water and DS Mud. The healing properties of DS minerals on skin have been well established by various researches. However, the beneficial mode of action of DS minerals on skin is not fully understood.

Osmoter™, a commercial and patented preparation of concentrated extracted DS water IP registered by "AHAVA-Dead Sea Laboratories" (AHAVA), exhibits various efficacies on skin and is implemented in all AHAVA skincare products.

Collaborating with leading universities and research centers, AHAVA has recently analyzed how human skin is affected by topical applied Osmoter™ in order to optimize its action, using innovative delivery strategies.

These studies revealed novel properties of Osmoter™ significantly contributing to skin health and well being phenotype in different modes of action related to biomarkers participating in skin barrier function, inflammation, redox status, aging process and photo-damage response.

The innovation regarding Osmoter™ and its effect on the different biomarkers in skin, which can pave the way for better therapeutic efficacy of both healthy and malfunctioning skin, will be discussed in the lecture-either by Osmoter™ itself, or either by its implementation in different topical preparations and in different concentrations.

Biography

Meital Portugal-Cohen has completed her Ph.D. in 2010 from School of Pharmacy, The Hebrew University of Jerusalem, Israel (thesis concerning skin clinical conditions related to oxidative stress). Since then, she is AHAVA project manager for research and development, supervisor for biological researches and represents the company in FP7 projects of the EU (i.e., "SkinTreat", "NanoTher", "NanoRetox", "SmartNano", and "SuperFlex"). She has published more than 10 papers in the scientific literature and contributed for 2 patents application.

Meital.P@Ahava.com